Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
aflibercept (zaltrap) (3 trials)
ranibizumab (lucentis) (3 trials)
Diabetic Retinopathy (Phase 2)
Edema (Phase 2)
Macular Edema (Phase 4)
Retinal Diseases (Phase 2)
Vascular Diseases (Phase 4)
Vitreous Hemorrhage (Phase 2)
Trials (6 total)
Trial APIs (2 total)